Vor's 'shielded' transplant delays relapse in leukemia patients

Plus: Summit's upcoming lung cancer study reveal

September 6, 2024 Check out STAT+

Sponsored By

CDC STAT+ | Vor Biopharma's 'shielded' transplant delays relapse in leukemia patients Eight of 10 patients with high-risk acute myeloid leukemia remain in remission after receiving a transplant, followed by maintenance treatment. By Adam Feuerstein STAT+ | Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal The upcoming HARMONi-2 presentation at the World Conference on Lung Cancer should indicate whether Summit's drug can chip away at the dominance of Keytruda. By Adam Feuerstein STAT+ | U.K. charities give $36 million to start new drugs for childhood tumors  The goal is to advance new molecules to a "drug candidate" stage, after which a company could take and advance it into early human trials. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser